BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 31585777)

  • 21. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.
    Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L
    Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
    Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
    Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach?
    Molina-Cerrillo J; Martínez-Sáez O; Alonso-Gordoa T; Tirado-Zambrano P; Delgado-Vargas B; Earl J; Grande E
    Clin Genitourin Cancer; 2015 Dec; 13(6):493-8. PubMed ID: 26027772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolution of bladder cancer genomics: What have we learned and how can we use it?
    Audenet F; Attalla K; Sfakianos JP
    Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder.
    Masuda N; Murakami K; Kita Y; Hamada A; Kamada M; Teramoto Y; Sakatani T; Matsumoto K; Sano T; Saito R; Okuno Y; Ogawa O; Kobayashi T
    Am J Pathol; 2020 Aug; 190(8):1752-1762. PubMed ID: 32339497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer.
    Guo CC; Majewski T; Zhang L; Yao H; Bondaruk J; Wang Y; Zhang S; Wang Z; Lee JG; Lee S; Cogdell D; Zhang M; Wei P; Grossman HB; Kamat A; Duplisea JJ; Ferguson JE; Huang H; Dadhania V; Gao J; Dinney C; Weinstein JN; Baggerly K; McConkey D; Czerniak B
    Cell Rep; 2019 May; 27(6):1781-1793.e4. PubMed ID: 31067463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sarcomatoid carcinoma associated with small cell carcinoma of the urinary bladder: a series of 28 cases.
    Urrea YR; Epstein JI
    Hum Pathol; 2017 Sep; 67():169-175. PubMed ID: 28827101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.
    Hoffman-Censits JH; Lombardo KA; Parimi V; Kamanda S; Choi W; Hahn NM; McConkey DJ; McGuire BM; Bivalacqua TJ; Kates M; Matoso A
    Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):619-625. PubMed ID: 33901032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
    Yang F; Zhou Q; Meng L; Xing N
    Medicine (Baltimore); 2019 Jul; 98(27):e16009. PubMed ID: 31277094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
    Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
    Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IMP3 expression in urothelial carcinomas of the urinary bladder.
    Ozdemir NO; Türk NS; Düzcan E
    Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.
    Wright JL; Black PC; Brown GA; Porter MP; Kamat AM; Dinney CP; Lin DW
    J Urol; 2007 Dec; 178(6):2302-6; discussion 2307. PubMed ID: 17936803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
    Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
    J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases.
    Fatima N; Canter DJ; Carthon BC; Kucuk O; Master VA; Nieh PT; Ogan K; Osunkoya AO
    Can J Urol; 2015 Jun; 22(3):7783-7. PubMed ID: 26068625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sarcomatoid carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 14 patients.
    Ikegami H; Iwasaki H; Ohjimi Y; Takeuchi T; Ariyoshi A; Kikuchi M
    Hum Pathol; 2000 Mar; 31(3):332-40. PubMed ID: 10746676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas.
    He F; Melamed J; Tang MS; Huang C; Wu XR
    Cancer Res; 2015 May; 75(10):2017-28. PubMed ID: 25795707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative Analysis of Genomic and Clinical Data Reveals Intrinsic Characteristics of Bladder Urothelial Carcinoma Progression.
    Zhou B; Guo R
    Genes (Basel); 2019 Jun; 10(6):. PubMed ID: 31212967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.